A review of novel analytical diagnostics for liquid biopsies: spectroscopic and spectrometric serum profiling of primary and secondary brain tumours

Katie Spalding; Ruth Board; Timothy Dawson; Michael D. Jenkinson; Matthew Baker

doi:10.1002/brb3.502

A review of novel analytical diagnostics for liquid biopsies: spectroscopic and spectrometric serum profiling of primary and secondary brain tumours

Katie Spalding, Ruth Board, Timothy Dawson, Michael D. Jenkinson, Matthew Baker

Pure And Applied Chemistry

Research output: Contribution to journal › Article

5 Citations (Scopus)

Abstract

With nearly 9,400 new cases of brain tumours diagnosed each year in the UK and over half of them resulting in death, the demand for a rapid, non-invasive diagnostic test permitting early detection is as vital and evident as ever. Brain tumours form when normal cells within the brain mutate, grow uncontrollably and form a mass. Brain tumours are stratified into increasing grades of malignancy determined by how they are likely to grow, the likelihood of reoccurrence and the likely best treatment, highlighted in Figure 1. Gliomas occur from the glial cells within the brain and central nervous system (CNS) are the most common primary brain tumour classified by World Health Organisation (WHO). Gliomas are often diagnosed late, are hard to treat and the prognosis is poor. Generally only 40% of patients with brain tumours are alive more than one year after diagnosis. Traditional treatment involves surgery, radiation therapy and chemotherapy but even with an extensive treatment plan survival is poor as symptoms are often diagnosed too late. The most common tumour types; astrocytomas, ependymomas and oligodendrogliomas have very different outcomes.

Language	English
Article number	e00502
Number of pages	8
Journal	Brain and Behavior
Early online date	29 Jun 2016
DOIs	10.1002/brb3.502
Publication status	E-pub ahead of print - 29 Jun 2016

Fingerprint

Biopsy

Brain Neoplasms

Tumors

Brain

Liquids

Serum

Glioma

Oligodendroglioma

Ependymoma

Astrocytoma

Routine Diagnostic Tests

Neuroglia

Chemotherapy

Neoplasms

Radiotherapy

Therapeutics

Central Nervous System

Neurology

Surgery

Drug Therapy

Keywords

liquid biopsies
brain tumours
early tumour detection
central nervous system

Cite this

Spalding, K., Board, R., Dawson, T., Jenkinson, M. D., & Baker, M. (2016). A review of novel analytical diagnostics for liquid biopsies: spectroscopic and spectrometric serum profiling of primary and secondary brain tumours. Brain and Behavior, [e00502]. https://doi.org/10.1002/brb3.502

Spalding, Katie ; Board, Ruth ; Dawson, Timothy ; Jenkinson, Michael D. ; Baker, Matthew. / A review of novel analytical diagnostics for liquid biopsies : spectroscopic and spectrometric serum profiling of primary and secondary brain tumours. In: Brain and Behavior. 2016.

@article{9e9d08ad0fb048998ed09d935b11eb78,

title = "A review of novel analytical diagnostics for liquid biopsies: spectroscopic and spectrometric serum profiling of primary and secondary brain tumours",

abstract = "With nearly 9,400 new cases of brain tumours diagnosed each year in the UK and over half of them resulting in death, the demand for a rapid, non-invasive diagnostic test permitting early detection is as vital and evident as ever. Brain tumours form when normal cells within the brain mutate, grow uncontrollably and form a mass. Brain tumours are stratified into increasing grades of malignancy determined by how they are likely to grow, the likelihood of reoccurrence and the likely best treatment, highlighted in Figure 1. Gliomas occur from the glial cells within the brain and central nervous system (CNS) are the most common primary brain tumour classified by World Health Organisation (WHO). Gliomas are often diagnosed late, are hard to treat and the prognosis is poor. Generally only 40{\%} of patients with brain tumours are alive more than one year after diagnosis. Traditional treatment involves surgery, radiation therapy and chemotherapy but even with an extensive treatment plan survival is poor as symptoms are often diagnosed too late. The most common tumour types; astrocytomas, ependymomas and oligodendrogliomas have very different outcomes.",

keywords = "liquid biopsies, brain tumours, early tumour detection, central nervous system",

author = "Katie Spalding and Ruth Board and Timothy Dawson and Jenkinson, {Michael D.} and Matthew Baker",

year = "2016",

month = "6",

day = "29",

doi = "10.1002/brb3.502",

language = "English",

journal = "Brain and Behavior",

issn = "2162-3279",

publisher = "Wiley-Blackwell",

}

Spalding, K, Board, R, Dawson, T, Jenkinson, MD & Baker, M 2016, 'A review of novel analytical diagnostics for liquid biopsies: spectroscopic and spectrometric serum profiling of primary and secondary brain tumours' Brain and Behavior. https://doi.org/10.1002/brb3.502

A review of novel analytical diagnostics for liquid biopsies : spectroscopic and spectrometric serum profiling of primary and secondary brain tumours. / Spalding, Katie; Board, Ruth; Dawson, Timothy; Jenkinson, Michael D.; Baker, Matthew.

In: Brain and Behavior, 29.06.2016.

Research output: Contribution to journal › Article

TY - JOUR

T1 - A review of novel analytical diagnostics for liquid biopsies

T2 - Brain and Behavior

AU - Spalding, Katie

AU - Board, Ruth

AU - Dawson, Timothy

AU - Jenkinson, Michael D.

AU - Baker, Matthew

PY - 2016/6/29

Y1 - 2016/6/29

N2 - With nearly 9,400 new cases of brain tumours diagnosed each year in the UK and over half of them resulting in death, the demand for a rapid, non-invasive diagnostic test permitting early detection is as vital and evident as ever. Brain tumours form when normal cells within the brain mutate, grow uncontrollably and form a mass. Brain tumours are stratified into increasing grades of malignancy determined by how they are likely to grow, the likelihood of reoccurrence and the likely best treatment, highlighted in Figure 1. Gliomas occur from the glial cells within the brain and central nervous system (CNS) are the most common primary brain tumour classified by World Health Organisation (WHO). Gliomas are often diagnosed late, are hard to treat and the prognosis is poor. Generally only 40% of patients with brain tumours are alive more than one year after diagnosis. Traditional treatment involves surgery, radiation therapy and chemotherapy but even with an extensive treatment plan survival is poor as symptoms are often diagnosed too late. The most common tumour types; astrocytomas, ependymomas and oligodendrogliomas have very different outcomes.

AB - With nearly 9,400 new cases of brain tumours diagnosed each year in the UK and over half of them resulting in death, the demand for a rapid, non-invasive diagnostic test permitting early detection is as vital and evident as ever. Brain tumours form when normal cells within the brain mutate, grow uncontrollably and form a mass. Brain tumours are stratified into increasing grades of malignancy determined by how they are likely to grow, the likelihood of reoccurrence and the likely best treatment, highlighted in Figure 1. Gliomas occur from the glial cells within the brain and central nervous system (CNS) are the most common primary brain tumour classified by World Health Organisation (WHO). Gliomas are often diagnosed late, are hard to treat and the prognosis is poor. Generally only 40% of patients with brain tumours are alive more than one year after diagnosis. Traditional treatment involves surgery, radiation therapy and chemotherapy but even with an extensive treatment plan survival is poor as symptoms are often diagnosed too late. The most common tumour types; astrocytomas, ependymomas and oligodendrogliomas have very different outcomes.

KW - liquid biopsies

KW - brain tumours

KW - early tumour detection

KW - central nervous system

UR - http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%292157-9032

U2 - 10.1002/brb3.502

DO - 10.1002/brb3.502

M3 - Article

JO - Brain and Behavior

JF - Brain and Behavior

SN - 2162-3279

M1 - e00502